About Us

History

HomeAbout UsHistory

ABL Bio History

History of ABL Bio

ABL Bio

2024

  • 07

    Paid-in capital increase allocated to a third party

  • 05

    Article about ABL503 published in CCR

2023

  • 11

    First dosed in phase 1 clinical trial of ABL103 in Korea

  • 08

    ABL103 Phase 1 clinical trial IND approved by MFDS

  • 07

    Article about ABL111 published in JITC

  • 03

    ABL503 Phase 1 clinical trial IND approved by MFDS

2022

  • 12

    First dosed in Phase 1 clinical trial of ABL301

  • 11

    Article about ABL301 published in Cell Reports Methods

  • 05

    Article about ABL501 published in Molecular Therapy

  • 03

    ABL111 received Orphan-Drug Designation

  • 01

    Signs licensing agreement with Sanofi

2021

  • 12

    re-certified as Korea Innovative Pharmaceutical Company

  • 08

    ABL501 Phase 1 clinical trial IND approved by MFDS

  • 07

    Review paper on bispecific antibody-based immunotherapy published in Vaccines

  • 06

    First patient dosed in Phase 1 clinical trial of ABL111

  • 04

    First patient dosed in Phase 1 clinical trial of ABL503

  • 03

    ABL111 phase 1 clinical trial IND approved by U.S. FDA

  • 02

    ABL001 Phase 2 clinical trial IND approved by MFDS

  • 01

    ABL503 Phase 1 clinical trial IND approved by U.S. FDA

  • 01

    ABL's 4-1BB bispecific antibody introduced in 'Science Advances'

  • 01

    ABL001 research published in International Journal of Molecular Sciences

2020

  • 10

    ABL and LegoChem sign licensing agreement with CStone Pharmaceuticals

  • 04

    ABL501 designated as National Project

  • 04

    Signs MOU with Samsung Medical Center for development of cancer immunotherapy

  • 03

    ABL001 Phase 1b/2a clinical trial approved by MFDS

2019

  • 02

    Signs licensing agreement with WuXi Biologics

  • 11

    Signs licensing agreement GenScript Biologics

  • 04

    Signs licensing agreement with TSD Life Sciences

  • 01

    Signs MOU with Genome & Company for development of immune checkpoint inhibitors

2018

  • 12

    ABL Bio IPO on KOSDAQ

  • 11

    Signs licensing agreement with Compass Therapeutics

  • 11

    Signs licensing agreement with TRIGR Therapeutics for ABL001

  • 09

    Signs licensing agreement with Yuhan

  • 07

    Signs joint development and licensing agreement with I-Mab Biopharma

  • 06

    Series C Funding (70 billion KRW)

2017

  • 08

    ABL001 Phase 1 clinical trial IND approved by MFDS

  • 03

    Series B Funding (20 billion KRW)

2016

  • 03

    Series A Funding (9 billion KRW)

  • 02

    Establishment of ABL Bio